Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131855) titled 'Etanercept suppresses rheumatoid arthritis development via modulating miR-125a-3p' on Sept. 7.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Qilu Hospital of Shandong University
Condition:
Rheumatoid arthritis
Intervention:
Test group:Etanercept injection (25 mg per pen/vial), a subcutaneous injection twice weekly at 25 mg per dose, combined with methotrexate (10-15 mg weekly, orally), for a treatment course of 12 weeks.
Recruitment Status: Not Recruiting
Phase: 1
Date of First Enrollment: 2022-08-17
Target Sample Size: Test group:20;Control group:20;
Countri...